Doxorubicin nanoparticles

Doxorubicin nanoparticles h incubation while a much higher and faster release of... 

Doxorubicin Nanoparticles The nanoparticles prepared were found to have the 63... 

Fig. 12 Left. Structure of ELP[VAgG7-160] conjugated to doxorubicin via the cysteine residues. Right. Self-assembly of ELP-Dox to form nanoparticles. Reprinted from [65] by permission from Macmillan Publishers Ltd Nature Materials, copyright 2009...

HS Yoo, JE Oh, KH Lee, TG Park. Biodegradable nanoparticles containing doxorubicin-PLGA conjugate for sustained release. Pharm Res 16(7) 1114-1118, 1999. 

Fig. 10 Multifunctional solid biodegradable PLGA nanoparticles attached to several moieties such as T-cell antibodies, magnetic resonance contrast agent (biotin-BSA-Gd-DTPA) and encapsulated immunosuppressive drug (doxorubicin). (Adapted from [48])...

MacKay JA, Chen M, McDaniel JR, Liu W, Simnick AJ, Chilkoti A (2009) Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat Mater 8 993-999... 

Bibby DC, Talmadge JE, Dalai MK, Kurz SG, Chytil KM, Barry SE, Shand DG, Steiert M (2005) Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. International Journal of Pharmaceutics 293 281-290. 

Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J (1999) Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 16 1564-1569. 

Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE (2004) Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 109 759-767... 

Figure 7 Release profiles of doxorubicin from the two nanoparticles free doxorubicin encapsulated nanoparticles and PLGA-doxorubicin loaded nanoparticles (adapted with permission from the publisher [24]).

Zara G.P., Intravenous administration to rahhits of non-stealth and stealth doxorubicin loaded sohd hpid nanoparticles at increasing concentrations of stealth agent pharmacokinetics and distrihution of doxoruhicin in hrain and other tissues, J. Drug Targeting, 10, 327, 2002. 

Fundaro A. et al.. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin pharmacokinetics and tissue distribution after i.v. administration to rats,... 

Soma, C. E., C. Dubernet, et al. (1999). Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm Res 16(11) 1710-6. 

Poly(alkyl cyanoacrylate) nanoparticles accumulate in the liver (60-90% of the injected dose) and the spleen upon iv injection, with the macrophages in the liver being their major target. Nanoparticles loaded with doxorubicin have shown a markedly enhanced therapeutic index in a number of animal tumor models. 

This is probably due to a reduction of the peak concentration of the drug in the cardiac tissue, the organ most severely affected by doxorubicin upon injection. Release of drug from the Kupffer cells upon breakdown of the nanoparticles in the lysosomal system (see Figure 5.2) may induce a slow release pattern that is still tumoricidal, but does not evoke the cardiotoxic effects. Another application where these nanoparticles have been shown to have large therapeutic promise is the killing of pathogens that are specifically located in the Kupffer cells in the liver. 

Yoo et al. [26] reported the antitumor activities of nanoparticles based on a doxorubicin-PLGA conjugate via the ester linkage that is expected to be more readily cleavable under physiological conditions. They have studied the antiu-mor activity in vivo by a subcutaneous route in comparison to the daily injection of doxorubicin and found that doxorubicin-PLGA conjugates are potentially useful for the treatment of tumors [26]. 

The hydrophilic delivery system described in this review can be extended to drugs with a low water-solubility (e.g., doxorubicin). Such compounds may be incorporated in CT/TPP nanoparticles by means of dextran sulfate complex prior to entrapment [54] or by dissolving them in a polar solvent (acetone, ethanol or acetonitrile) as demonstrated for the relatively hydrophobic peptide cyclosporin A [26,81]. It is quite possible that this approach would work in a multicomponent polymer system as well. 

Leo E, Vandelli MA, Cameroni R, Fomi F (1997) Doxorubicin-loaded gelatin nanoparticles stabilized by glutaraldehyde involvement of the drug in the cross-linking process. Int J Pharm 155(l) 75-82... 

Thermosensitive block copolymer nanoparticles containing doxorubicin increased cytotoxicity against Lewis lung carcinoma cells when activated by heating above the LCST [139], Chitosan was chemically conjugated to NIPAAm/vinyl laurate copolymer to enhance gene transfection in mouse myoblast cells [140]. Upon i.v. administration, poly(NIPAAm) nanoparticles are taken up by the reticuloendothelial cells of the liver and mild inflammatory and fibrotic responses are observed... 

Leo, E., Arletti, R., Forni, F., and Cameroni, R. (1997), General and cardiac toxicity of doxorubicin-loaded gelatin nanoparticles, Farmaco, 52(6-7), 385-388. 

New functions can be obtained by modifications of SLNs. Incorporation of Tween 80 and Poloxamer 188 can stabilize SLNs to achieve long-circulating or crossing blood-brain barrier effects [112], Recently, novel nanoparticles called polymer-lipid hybrid nanoparticles (PLNs) were developed [113]. They can entrap cationic anticancer agents (e.g., doxorubicin) effectively by incorporation of an anionic lipophilic polymer into lipids to treat multidrug-resistant (MDR) cancers. 

Wong, H. L., Bendayan, R., Rauth, A. M., and Wu, X. Y. (2006), Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer, J. Controlled... 

---